Kamada Ltd. (NASDAQ:KMDA) Sees Large Increase in Short Interest

Key Points

• Kamada Ltd. saw a significant increase in short interest in August, rising by 41.4% to 66,900 shares, with a days-to-cover ratio of 1.1 days.
• Institutional investors hold approximately 20.38% of Kamada's stock, with notable stakes acquired by firms like Acadian Asset Management and ARK Investment Management.
• Analysts have a consensus rating of “Moderate Buy” for Kamada, with a price target of $13.00, while the stock recently traded at $7.22.

Kamada Ltd. (NASDAQ:KMDA - Get Free Report) saw a significant increase in short interest in the month of August. As of August 15th, there was short interest totaling 66,900 shares, an increase of 41.4% from the July 31st total of 47,300 shares. Based on an average daily trading volume, of 63,100 shares, the days-to-cover ratio is presently 1.1 days. Approximately 0.2% of the company's shares are short sold. Approximately 0.2% of the company's shares are short sold. Based on an average daily trading volume, of 63,100 shares, the days-to-cover ratio is presently 1.1 days.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Acadian Asset Management LLC lifted its stake in shares of Kamada by 3.1% in the second quarter. Acadian Asset Management LLC now owns 263,556 shares of the biotechnology company's stock valued at $2,053,000 after buying an additional 7,925 shares in the last quarter. ARK Investment Management LLC purchased a new stake in shares of Kamada in the second quarter valued at about $1,972,000. Huntleigh Advisors Inc. raised its holdings in shares of Kamada by 3.9% in the second quarter. Huntleigh Advisors Inc. now owns 135,776 shares of the biotechnology company's stock valued at $1,052,000 after purchasing an additional 5,151 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Kamada in the first quarter valued at about $582,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Kamada in the first quarter valued at about $497,000. 20.38% of the stock is owned by institutional investors.

Kamada Trading Up 0.1%

NASDAQ KMDA traded up $0.01 on Friday, hitting $7.02. 25,758 shares of the company were exchanged, compared to its average volume of 47,511. The company has a market cap of $403.72 million, a PE ratio of 20.65, a PEG ratio of 0.74 and a beta of 0.89. Kamada has a 12 month low of $5.17 and a 12 month high of $9.15. The stock has a fifty day moving average of $7.33 and a 200-day moving average of $7.01.

Kamada (NASDAQ:KMDA - Get Free Report) last issued its earnings results on Wednesday, August 13th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.04. The business had revenue of $44.75 million for the quarter, compared to analyst estimates of $158.59 million. Kamada had a net margin of 11.22% and a return on equity of 7.41%. Kamada has set its FY 2025 guidance at EPS. On average, analysts expect that Kamada will post 0.23 earnings per share for the current year.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Kamada from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, May 21st. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $13.00.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.